Three percent of patients given Acomplia (rimonabant) dropped out of studies due to depression compared to 1.4 percent given a placebo according to an analysis by Arnie Astrup and others from the University of Copenhagen in Frederiksberg, Denmark. This means that dropouts due to depression are 2.5 times as likely with Acomplia (rimonabant) than with placebo.
This is despite the fact that “[all of] the included trials excluded patients with existing depression, or those with a history [of depression],” Astrup noted.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.